Another robot deal for J&J shows up lack of Verb results
Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.
Astra guns for quick cancer and lupus filings
Questions about clinical data aside, Imfinzi and tremelimumab could be filed for first-line lung cancer by the end of the year.
Bristol might play a role in front-line lung cancer after all
The Checkmate-9LA trial of Opdivo plus Yervoy yesterday read out positively for overall survival.
Vertex’s double cystic fibrosis surprise
The remarkable speed of the company’s cystic fibrosis triplet approval will not distract attention from its price.
Shock revelation sees Biogen erase its aducanumab losses
The amyloid-beta project is to be filed for Alzheimer’s, and Biogen’s market cap regains the $15bn it lost in March.
Strong Zolgensma start bodes ill for Biogen
Zolgensma’s impressive early sales figures spur hopes that gene therapy could finally be coming of age.
Vindication is sweet for Seattle
Tucatinib yields a positive result in breast cancer, vindicating Seattle Genetics’ acquisition of its originator.
Bavarian’s chance to draw a line under oncology
The Danish group seizes an opportunity to focus on what it does best, but its ill-fated flirtation with oncology continues.
Kiadis falls, and Bellicum could be next
EU rejection of Kiadis's stem cell transplant adjunct means that two of three players in this space have been knocked back.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.